

Datasheet for ABIN500006

anti-IL-31 antibody (Intermediate Domain)






Goto	Product	nage
90 10	FIUUUUU	paye

	ve	rv	ie	W
\circ	v C	· I V	10	V V

Overview	
Quantity:	0.1 mg
Target:	IL-31 (IL31)
Binding Specificity:	Intermediate Domain
Reactivity:	Human, Mouse
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This IL-31 antibody is un-conjugated
Application:	Western Blotting (WB), Enzyme Immunoassay (EIA)
Product Details	
Immunogen:	Human IL-31 (Intermediate Domain) Peptide
Isotype:	IgG
Specificity:	IL-31 antibody was raised against a 18 amino acid peptide from near the center of human IL-31.
Purification:	Affinity chromatography purified via peptide column
Target Details	
Target:	IL-31 (IL31)
Alternative Name:	Interleukin-31 / IL31 (IL31 Products)
Background:	Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells (1,2). IL-31 activity is mediated

	through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor (2). In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways (3). RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells . IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development (1,4). Synonyms: IL-31
Gene ID:	386653
NCBI Accession:	NP_001014358
UniProt:	Q6EBC2
Application Details	
Application Notes:	ELISA. Western Blot: 2.5 - 5 µg/mL. Despite its predicted size, IL-31 runs at approximately 27 - 30 kDa in SDS-PAGE. Other applications not tested.
	Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions:	
Restrictions: Handling	Optimal dilutions are dependent on conditions and should be determined by the user.
	Optimal dilutions are dependent on conditions and should be determined by the user.
Handling	Optimal dilutions are dependent on conditions and should be determined by the user. For Research Use only
Handling Buffer:	Optimal dilutions are dependent on conditions and should be determined by the user. For Research Use only PBS containing 0.02 % sodium azide.



Western Blotting

Image 1. Western blot analysis of IL-31 in human skeletal muscle tissue lysate with AP30423PU-N IL-31 antibody at (A) 2.5, (B) 5 and (C) 10 μ g/ml.